Efficacy, metabolic characteristics, safety and immunogenicity of AK-HER2 compared with reference trastuzumab in patients with metastatic HER2-positive breast cancer: a multicenter, randomized, double-blind phase Ⅲ equivalence trial

Efficacy, metabolic characteristics, safety and immunogenicity of AK-HER2 compared with reference trastuzumab in patients with metastatic HER2-positive breast cancer: a multicenter, randomized, double-blind phase Ⅲ equivalence trial

Background and purpose: For patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer, trastuzumab treatment can prolong the overall survival and significantly improve the prognosis of patients. However, the reference original research trastuzumab (Herceptin®) i...

Deskribapen osoa

Xehetasun bibliografikoak
Egile nagusia: LUO Yang, SUN Tao, SHAO Zhimin, CUI Jiuwei, PAN Yueyin, ZHANG Qingyuan, CHENG Ying, LI huiping, YANG Yan, YE Changsheng, YU Guohua, WANG Jingfen, LIU Yunjiang, LIU Xinlan, ZHOU Yuhong, BAI Yuju, GU Yuanting, WANG Xiaojia, XU Binghe, SONG Lihua
Formatua: Artikulua
Hizkuntza:English
Argitaratua: Editorial Office of China Oncology 2024-02-01
Saila:Zhongguo aizheng zazhi
Gaiak:
|breast cancer|trastuzumab|ak-her2|efficacy|pharmacokinetics|safety
Sarrera elektronikoa:http://www.china-oncology.com/fileup/1007-3639/PDF/1710376744524-919017700.pdf

Internet

http://www.china-oncology.com/fileup/1007-3639/PDF/1710376744524-919017700.pdf

Antzeko izenburuak